RARE DISEASE COMPANY COALITION

Lobbying for RARE DISEASE COMPANY COALITION · Healthcare

Filing 1st Quarter - Amendment

Reporting period

1st Quarter 2025

Jan 1 - Mar 31 · Posted Apr 21, 2025

Expenses

$60,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 6

HR 4758
Accelerating Kids’ Access to Care Act
HR 1262
Mikaela Naylon Give Kids a Chance Act
HR 946
ORPHAN Cures Act
HR 1414
Cameron’s Law
HR 7384
Creating Hope Reauthorization Act of 2024
HR 1532
Scientific EXPERT Act of 2025

Lobbying activity 3

Medicare/Medicaid

HR 4758 - Accelerating Kids Access to Care Act

Pharmacy

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 3131 - ORPHAN Cures Act Technical Correction to IRA Orphan Exception HR 1414 - Camerons Law Orphan Drug Tax Credit HR 7384 - Creating Hope Reauthorization Act of 2024 S 4583 - Creating Hope Reauthorization Act of 2024

Science/Technology

HR 1532 - Scientific EXPERT Act of 2025 S 822 - Scientific EXPERT Act of 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.